N@N

Market Maker Surveillance Report. MCP, MAPP, ZIOP, FIZZ, CCCL, BGMD, Winning Stocks With Lowest Price Friction For Friday, Nov

November 23, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 3494 companies with "abnormal" market making, 3901 companies with positive Friction Factors and 1193 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Molycorp Inc (NYSE:MCP), MAP Pharmaceuticals Inc (NASDAQ:MAPP), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), National Beverage Corp (NASDAQ:FIZZ), China Ceramics Co Ltd (NASDAQ:CCCL), BG Medicine Inc (NASDAQ:BGMD). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  MCP     $1.360    18.81%    4,728,969    36.76%    4,664,035    36.26%    64,934       477     
  MAPP    $2.600    20.28%    569,388      49.95%    556,300      48.80%    13,088       50      
  ZIOP    $0.630    14.65%    219,095      55.78%    173,682      44.22%    45,413       721     
  FIZZ    $2.170    14.74%    85,282       59.59%    48,132       33.63%    37,150       171     
  CCCL    $0.710    41.76%    475,942      55.17%    386,136      44.76%    89,806       1,265   
  BGMD    $0.290    23.02%    359,349      50.46%    340,494      47.82%    18,855       650     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows MCP with a dollar gain Friday of $1.36000 and a Friction Factor of 477 shares. That means that it only took 477 more shares of buying than selling to move MCP higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Molycorp Inc (NYSE:MCP) - Molycorp, Inc., a development stage company, focuses on the production and sale of rare earth oxides from stockpiled feedstocks in the western hemisphere. The company operates the Mountain Pass mine, a non-Chinese rare earth deposit located in San Bernardino County, California. Its rare earth products are used as inputs in various existing and emerging applications comprising clean energy technologies; multiple high-tech uses; defense applications; and water treatment technology. The company was founded in 2008 and is headquartered in Greenwood Village, Colorado..

MAP Pharmaceuticals Inc (NASDAQ:MAPP) - MAP Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of inhalation therapies for patients suffering from migraine. It is developing LEVADEX, which is in Phase III clinical trials for the treatment of migraine through oral inhalation. The company is also developing two earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. has collaborations and license agreements with Elan Pharma International Limited, Nektar Therapeutics UK Limited, Exemplar Pharmaceuticals, LLC, and Allergan Inc. The company was founded in 2003 and is based in Mountain View, California..

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of a portfolio of cancer drugs in North America. Its products under various stages of development and trials include Palifosfamide for the treatment of sarcoma, lymphoma, testicular, and other cancers; Darinaparsin, a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers; and Indibulin, an oral tubulin binding agent that targets mitosis and cancer cell migration. The company has license agreements with DEKK-Tec, Inc.; and Baxter Healthcare Corporation, as well as a collaboration agreement Harmon Hill, LLC. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York..

National Beverage Corp (NASDAQ:FIZZ) - National Beverage Corp. develops, manufactures, markets, and distributes various beverage products in the United States. It offers a selection of flavored soft drinks, juices and other specialty beverages, sparkling waters, energy drinks, and nutritionally-enhanced waters. The company provides its soft drink products under the Shasta and Faygo names. It also offers juice and juice-based products under Everfresh, Home Juice, and Mr. Pure names; flavored, sparkling, and spring water products under LaCroix, Crystal Bay, and ClearFruit names; and nutritionally-enhanced waters under ASante name. In addition, the company distributes energy drinks under the Rip It, fruit-flavored drinks under the Ohana, holiday soft drinks under the St. Nicks, and powder and tablet beverage enhancers under the NutraFizz names. Further, it develops and produces soft drinks for retailers and beverage companies. The companys customers include national and regional retailers, mass merchandisers, wholesalers, and discount stores, as well as hospitals, schools, military bases, airlines, hotels, and food-service wholesalers. National Beverage provides its products through national and regional grocery stores, warehouse clubs, mass-merchandisers, wholesalers and dollar stores, convenience stores, gas stations, and independent and specialized distributors, as well as through direct store distribution facilities. The company was founded in 1985 and is based in Ft. Lauderdale, Florida..

China Ceramics Co Ltd (NASDAQ:CCCL) - China Ceramics Co., Ltd. engages in the manufacture and sale of ceramic tiles used for exterior siding, interior flooring, and design in residential and commercial buildings primarily in the People's Republic of China. The company offers porcelain tiles, glazed tiles, glazed porcelain tiles, rustic tiles, and ultra-thin tiles under the HD or Hengda brand name. It primarily sells its products through a distributor network, as well as directly to property developers. The company is based in Jinjiang City, the People's Republic of China..

BG Medicine Inc (NASDAQ:BGMD) - BG Medicine, Inc., a life sciences company, engages in the discovery, development, and commercialization of molecular diagnostics based on biomarkers in the United States. Its product pipeline includes molecular diagnostics for cardiovascular diseases, such as congestive heart failure, coronary stenosis, and vulnerable plaque; cancers; and CNS disorders, including alzheimer's disease and multiple sclerosis, as well as for patients receiving Tysabri, a treatment that is associated with a side effect. The company also provides Avandia, a drug for the treatment of Type II diabetes; and Enbrel and Remicade, which are treatments indicated for autoimmune disorders, such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease, and other related conditions. In addition, it offers disease mechanisms, drug mechanisms, drug efficacy, drug toxicity, responder identification, and translational medicine services. The company has a research collaboration with Merck & Co. Inc. for the development and validation of a novel biomarker with potential application in the management of lipid disorders. The company was founded in 2000 as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in November 2004. BG Medicine, Inc. is headquartered in Waltham, Massachusetts..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net